Indivior/$INDV
1D1W1MYTD1Y5YMAX
Capital at risk
About Indivior
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
- Ticker
- $INDV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 833
- Headquarters
- North Chesterfield, United States
- Website
- www.indivior.com
Indivior Metrics
BasicAdvanced
$4B
12.36
$2.77
1.14
-
Price and volume
Market cap
$4B
Beta
1.14
52-week high
$42.81
52-week low
$27.68
Average daily volume
2.3M
Financial strength
Current ratio
0.835
Quick ratio
0.586
Long term debt to equity
-2.404
Total debt to equity
-2.447
Interest coverage (TTM)
21.00%
Profitability
EBITDA (TTM)
576
Gross margin (TTM)
85.73%
Net profit margin (TTM)
26.75%
Operating margin (TTM)
42.07%
Effective tax rate (TTM)
9.64%
Revenue per employee (TTM)
$1,600,000
Management effectiveness
Return on assets (TTM)
26.07%
Return on equity (TTM)
-153.12%
Valuation
Price to earnings (TTM)
12.365
Price to revenue (TTM)
3.175
Price to book
-19.41
Price to tangible book (TTM)
-19.23
Price to free cash flow (TTM)
-38.074
Free cash flow yield (TTM)
-2.63%
Free cash flow per share (TTM)
-0.899
Growth
Revenue change (TTM)
13.47%
Earnings per share change (TTM)
227.70%
3-year revenue growth (CAGR)
9.93%
10-year revenue growth (CAGR)
2.62%
3-year earnings per share growth (CAGR)
86.01%
10-year earnings per share growth (CAGR)
8.26%
Bulls say / Bears say
Indivior delivered Q1 2026 total net revenue of $317 million, a 19% year-over-year increase driven by robust uptake of SUBLOCADE (TradingView).
Record Q1 2026 adjusted EBITDA surged 112% year-over-year to $164 million, underscoring strong operational leverage and effective cost management (Investing.com).
Management raised full-year 2026 guidance, lifting net revenue outlook to $1.215 billion–$1.285 billion and adjusted EBITDA guidance to $620 million–$660 million, reflecting confidence in sustained growth (Stockopedia).
Q2 revenue growth decelerated to 14% year-on-year in Q2 2026, down from 19% in Q1 2026, suggesting potential slowing of Indivior’s core sales momentum (Bitget News).
Indivior’s high reliance on its buprenorphine franchise faces future risk as patents for its key products expire between 2031 and 2038, exposing revenues to potential generic or biosimilar competition that could significantly erode sales (SEC).
The announced all-stock merger of equals with Supernus Pharmaceuticals may dilute existing shareholders and poses integration and execution risks that could distract management and impact near-term operational focus (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.
Upcoming events
No upcoming events
Indivior News
AllArticlesVideos
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire3 weeks ago
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Business Wire1 month ago
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire1 month ago
Funds containing Indivior
AllUSDGBPEUR
Fund name | Fund size | $INDV weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.28% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.28% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.24% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.24% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.